1312 results about "Cytotoxicity" patented technology

The invention relates to the technical field of antibacterial peptides, and particularly discloses a marine antibacterial peptide and application thereof, and the amino acid sequence of the marine antibacterial peptide is as shown in SEQ ID NO.1: MWKLPKWRNGRRRGFKIPRW. The marine antibacterial peptide CD109 provided by the invention has an inhibition effect on staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa and klebsiella pneumoniae, and has extremely low cytotoxicity.

Sonodynamic therapy systems and methods use short, high-pressure ultrasound pulses that produce small (and therefore clinically safe) increases (up to 1-2° C.) in tissue temperature but nonetheless activate sonodynamic agents, allowing isolated single-cav-itation events to produce therapeutically beneficial effects (e.g., cytotoxicity) on diseased tissue. An escalating sonication strategy may be employed whereby the focal pressure is gradually increased until maximum clinically tolerable parameters such as the degree of heating of intervening tissue (e.g., the skull when treating brain cancer) or undesired induced cavitation effects are reached.

The invention belongs to the technical field of cosmetics, and discloses anti-aging recombinant collagen as well as a preparation method and application thereof. The amino acid sequence of the anti-aging recombinant collagen is as shown in SEQ ID NO.1, and the nucleotide sequence of the anti-aging recombinant collagen is as shown in SEQ ID NO.2. The recombinant collagen CaI1 is constructed and expressed by recombining the effective sequences of the I-type collagen, the III-type collagen and the XVII-type collagen, and the recombinant collagen CaI1 is free of cytotoxicity, free of hidden danger of endotoxin and good in safety. The skin care product added with the recombinant collagen CaI1 can promote skin collagen absorption, inhibit skin aging and improve skin elasticity, and has a good application prospect.

The invention relates to a plant lactobacillus JN9, a preparation, a probiotic composition and application thereof. According to the application, a new plant lactobacillus JN9 strain is obtained through screening, and the preservation number of the new plant lactobacillus JN9 strain is CCTCC (China Center for Type Culture Collection) NO: M 20241647. Through basic characteristic analysis (growth curve, acid resistance, cholate resistance and gastrointestinal fluid resistance), safety evaluation (antibiotic sensitivity, hemolysis capability, toxin production capability, cytotoxicity and biogenic amine production capability), adhesiveness evaluation, GABA production evaluation and alcohol tolerance and acetaldehyde dehydrogenase production capability evaluation of the strain, the strain is found to be a safe strain; and the GABA has excellent GABA production performance, high alcohol tolerance and high acetaldehyde dehydrogenase activity. The composition can be applied to products for improving mood, such as relieving pressure, resisting depression, improving body sleep quality, reducing blood pressure, resisting diabetes, resisting cancer, resisting oxidation, resisting inflammation, resisting microorganisms, resisting allergy, enhancing alcohol tolerance in drinking, relieving discomfort after drinking and the like.

The invention provides a broad-spectrum antibacterial peptide, an antibacterial agent and application, and belongs to the technical field of biological medicine. The invention provides a broad-spectrum antibacterial peptide. The broad-spectrum antibacterial peptide comprises an amino acid sequence as shown in SEQ ID No. 1. The minimum inhibitory concentration of the antibacterial peptide to gram-positive bacteria, gram-negative bacteria and fungi proves that the antibacterial peptide has obvious antibacterial activity to the gram-positive bacteria, the gram-negative bacteria and the fungi. The invention also verifies the minimum inhibitory concentration of the antibacterial peptide to clinical drug-resistant bacteria. The cytotoxicity of the SL-12 disclosed by the invention is relatively weak, the SL-12 only shows obvious cytotoxicity at 200 [mu] g / ml, and the minimum inhibitory concentration of the SL-12 is 6.25-12.5 [mu] g / ml; the SL-12 has no obvious hemolytic activity when the concentration is 100 [mu] g / ml or lower, and is high in safety.

The invention relates to the technical field of antibacterial peptide application, in particular to an antibacterial peptide for inhibiting drug-resistant acinetobacter baumannii as well as a preparation method and application of the antibacterial peptide. The antibacterial peptide is cd77AHP-2, and the amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1. The antibacterial peptide cd77 obtained through artificial chemical synthesis is modified, distribution of cationic amino acid is optimized, and the antibacterial activity of the antibacterial peptide is remarkably improved. The antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on acinetobacter baumannii which are gram-negative bacteria and multi-drug resistant acinetobacter baumannii, and the antibacterial peptide cd77AHP-2 has a remarkable antibacterial effect on the acinetobacter baumannii which are gram-negative bacteria. The antibacterial peptide cd77AHP-2 provided by the invention has relatively low cytotoxicity to human bronchial epithelial cells, and has the potential of preparing a drug for resisting drug-resistant acinetobacter baumannii. The invention provides a novel functional polypeptide for the field of antibacterial peptides, and the novel functional polypeptide has important practical application value.

The invention discloses a milk-derived broad-spectrum antibacterial peptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the antibacterial peptide is as shown in any one of SEQ ID NO.2-6. Five novel antibacterial peptides are obtained by carrying out symmetrical structure design and amino acid mutation on the basis of a template peptide, and tests find that the five novel antibacterial peptides have broad-spectrum antibacterial activity which is obviously higher than that of the template peptide, and basically have no cytotoxicity. Wherein the geometric mean (GM) of the minimum inhibitory concentration can reach 3.60, and the therapeutic index (TI) can reach 71.11. The antibacterial peptide prepared by the invention still keeps good antibacterial activity in physiological salt concentration and protease environment, has certain serum stability, and has higher application value; in addition, the antibacterial peptide has a good inhibition effect on the formation of a bacterial biofilm, and has a synergistic effect with traditional antibiotics.

The invention relates to the technical field of biology, and particularly discloses a recombinant collagen III and application thereof in preparation of gel. The recombinant collagen III is designed by optimizing functional area sequences of human I-type and III-type collagen, the amino acid sequence is shown as SEQ ID No.2, and the recombinant collagen III has the characteristics of high stability, good hydrophilicity and low immunogenicity. The preparation method comprises the steps of expression vector construction, escherichia coli induced expression, affinity chromatography purification and renaturation. The recombinant collagen III can be prepared into a gel dressing and comprises sodium alginate, methylparaben and other components. Experiments show that the gel can effectively promote cell proliferation and has no cytotoxicity; in a mouse skin injury model, the collagen can relieve inflammation, accelerate wound healing and inhibit scar formation, and the effect of the collagen is superior to that of natural human III-type collagen. The invention provides a safe and efficient novel material for wound repair, and is suitable for medical dressings and tissue engineering.

The invention belongs to the technical field of antibacterial peptides, and particularly relates to an antibacterial peptide and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1, the number of amino acids is small, the synthesis cost is low, the antibacterial peptide has high antibacterial activity on gram-negative bacteria and gram-positive bacteria, the minimum inhibitory concentration of the antibacterial peptide on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is 4.68-37.5 mu g / mL, and the antibacterial peptide has the advantages of broad-spectrum antibacterial property, good stability and good application prospect. No obvious cytotoxicity and hemolysis effect exist; moreover, end-to-end amido bond cyclization is carried out, so that the antibacterial activity is further enhanced, the antibacterial effect on acinetobacter baumannii, escherichia coli, pseudomonas aeruginosa and staphylococcus aureus is enhanced by 2-4 times, and the minimum inhibitory concentration is reduced to 2.34-9.38 mu g / mL; after the end-to-end amido bonds are cyclized, the plasma stability and safety of the antibacterial peptide are further improved, and the cytotoxicity and hemolysis are reduced.

The invention belongs to the technical field of biological medicines, and relates to an antibacterial polypeptide, a composition and application thereof. The amino acid sequence of the antibacterial polypeptide is as shown in SEQ ID NO. 1: KWKIKWPVKWFKM-NH2. The invention also discloses a preparation method of the antibacterial polypeptide. Experiments show that the antibacterial polypeptide disclosed by the invention has broad-spectrum antibacterial activity on gram-positive bacteria and / or gram-negative bacteria, and also has low cytotoxicity and low hemolysis. The antibacterial polypeptide provided by the invention consists of 14 amino acids, is relatively short in peptide chain, small in molecular weight and easy to artificially synthesize, is a micromolecular polypeptide with extremely high application value, can be used for preparing a novel antibacterial agent, and has a wide application prospect.

The invention provides an antibacterial peptide and application thereof, and belongs to the technical field of biological medicine. Based on bioinformatics and an AI technology, a novel broad-spectrum antibacterial peptide is expected to be screened from tick (hard tick shoulder) genomes, and the antibacterial peptide has antibacterial activity on bacteria (including clinical drug-resistant strains) and fungi, does not have obvious cytotoxicity and hemolytic activity, and is an important candidate molecule of anti-infective drugs. In the embodiment of the invention, the minimum inhibitory concentration of the antibacterial peptide on gram-positive bacteria, gram-negative bacteria and fungi is verified, and the antibacterial peptide is proved to have obvious antibacterial activity on the gram-positive bacteria, the gram-negative bacteria and the fungi. The invention also verifies that the minimum inhibitory concentration of the antibacterial peptide to clinical drug-resistant bacteria is equivalent to the minimum inhibitory concentration of the antibacterial peptide to standard strains, and verifies that the antibacterial peptide can be used as a broad-spectrum antibacterial peptide and is named as SL-15.

To provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an anti-cadherin 17 antibody comprising a heavy chain variable region and a light chain variable region, a drug conjugate thereof, and a composition containing the anti-cadherin 17 antibody or the drug conjugate thereof, and an application thereof as a drug.

The invention is applicable to the technical field of polypeptides, and provides a novel antibacterial peptide GG25 and application thereof, and the amino acid sequence of the antibacterial peptide GG25 is as shown in SEQ ID No.1. The molecular weight of the novel antibacterial peptide GG25 is 2890.52 Da, and the novel antibacterial peptide GG25 has antibacterial activity on escherichia coli, klebsiella pneumoniae, pseudomonas aeruginosa, enterococcus faecalis, salmonella typhimurium, methicillin-resistant staphylococcus aureus, staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes and bacillus subtilis; the hemolytic activity is low, the cytotoxicity is small, and the escherichia coli and methicillin-resistant staphylococcus aureus are not easily induced to generate drug resistance; in addition, the gelatin chitosan food coating containing GG25 also has a good beef preservation effect, and can be applied to the fields of food, animal husbandry, medicine and the like.

The invention discloses a preparation method of a three-dimensional porous white phosphorus calcium stone ceramic bracket with piezoelectric biological activity, and belongs to the field of brackets. The preparation method of the scaffold comprises the following steps: uniformly dipping a polymer foam template with a certain pore size and porosity in slurry composed of beta-tricalcium phosphate and a binder, carrying out high-temperature sintering to remove organic matters, carrying out a hydrothermal reaction on the inorganic scaffold in an aqueous solution containing magnesium ions, converting beta-tricalcium phosphate into white calcomanite, and carrying out drying to obtain the scaffold. And then carrying out high-temperature annealing treatment to obtain the white calcomanite porous ceramic bracket with piezoelectric biological activity. The prepared ceramic scaffold is controllable in composition and degradation rate, excellent in mechanical property, electroactive, free of cytotoxicity and remarkable in osteogenesis induction effect, and the porosity and aperture of the scaffold are suitable for cells to enter and grow. The preparation method of the white phosphorite three-dimensional piezoelectric ceramic bracket is simple and easy to implement, controllable in process and easy to amplify.

The invention provides a thiazolidinone compound and application thereof in preparation of drugs for resisting staphylococcus aureus infection. The molecular structural formula of the thiazolidinone compound is shown as a formula (1), a formula (2), a formula (3) or a formula (4). The technical scheme of the invention discloses several thiazolidinone compounds, which not only have an excellent bactericidal effect on staphylococcus aureus and can significantly inhibit the formation of a biofilm of staphylococcus aureus, but also have low cytotoxicity and hemolytic activity. According to the technical scheme, a certain foundation is laid for research and development of novel staphylococcus aureus biofilm infection resisting drugs, and the potential of thiazolidone derivatives for developing novel antibacterial agents for staphylococcus aureus related infection can be deeply known possibly.

The invention discloses application of scylla serrata antibacterial peptide Scycin in preparation of an anti-inflammatory composition and a preparation method of the scylla serrata antibacterial peptide Scycin. The nucleotide sequence of the scylla serrata antibacterial peptide Scycin is shown as SEQ ID NO.01. The invention further discloses a preparation method of the scylla serrata antibacterial peptide Scycin. In an LPS (lipopolysaccharide)-induced RAW 264.7 macrophage inflammation model, the recombinant expression plasmid vector containing the scylla antibacterial peptide Scin remarkably inhibits an inflammation cascade reaction by down-regulating expression of proinflammatory factors such as TNF-alpha (tumor necrosis factor-alpha) and IL-6 (interleukin-6), the anti-inflammatory effect of the recombinant expression plasmid vector is equivalent to that of a mesalazine positive control group, and obvious cytotoxicity is not observed.

The invention relates to the technical field of medicines, in particular to a curcumin-loaded engineered cell membrane nano-vesicle NVs-CUR and a preparation method thereof, and the preparation method comprises the following steps: S1, extruding a macrophage suspension through an extruder to obtain an NVs resuspension; and S2, adding the CUR mixed solution into the NVs resuspension solution, and carrying out ultrasonic treatment to obtain the nano vesicle NVs-CUR. As a novel drug delivery system, the NVs-CUR shows excellent performance in the aspects of physical stability, drug release and stability, cellular uptake ability, cytotoxicity and the like. The characteristics provide powerful support for application in treatment of diseases such as nerve injury and the like, and indicate the wide prospect in the field of biomedicine.

The invention provides a coding gene of coral-derived anticoagulant polypeptide and application, and belongs to the technical field of bioactive peptides. The invention provides an anticoagulant polypeptide GcKuz1. The anticoagulant polypeptide GcKuz1 comprises a mature peptide fragment as shown in SEQ ID No.1. The invention also provides a preparation method of the anticoagulant polypeptide GcKuz1. The polypeptide GcKuz1 is combined with KLKB1 in a thrombin system, so that the anti-thrombus and anti-coagulation effects are achieved, and the polypeptide does not cause hemolysis and cytotoxicity, has no bleeding risk and has good biological safety. The anticoagulant polypeptide disclosed by the invention has the effect of treating thrombotic diseases, such as arterial thrombotic diseases, venous thrombotic diseases and capillary thrombotic diseases.

The invention relates to an anti-cryptosporidium micromolecular lead compound of a target cryptosporidium helicase. Comprising the following steps: S1, detecting enzyme activity parameters of a drug target helicase (CpeIF4A) and an inhibition effect of Roc-A on the drug target helicase: expressing and purifying a CpeIF4A recombinant protein containing an MBP tag; detecting the enzyme activity; detecting the inhibition effect of the Roc-A on the enzyme activity; determining the affinity between the Roc-A and the CpeIF4A through a heat transfer experiment; s2, in-vitro drug effect determination: evaluating the direct killing capability of Roc-A on sporozoites; the inhibition effect of Roc-A on cryptosporidium is determined through an in-vitro cell infection model, an EC50 value is obtained, and the intracellular period of the Roc-A mainly playing the inhibition effect is determined; detecting the toxicity of Roc-A to host cells to obtain a TC5 value), and obtaining an in-vitro insect-resistant selectivity index (SI); and S3, in-vivo drug effect test: establishing a C57BL / 6IFN-gamma gene knockout mouse infection model to evaluate the effectiveness and safety of Roc-A. The invention determines that the Roc-A has the potential of being further developed into the cryptosporidium-resistant drug, and verifies that the targeted eIF4A can resist cryptosporidium infection.

A photosensitizer chimera targeting PD-L1 protein, and a preparation method therefor and a use thereof. The photosensitizer chimera is of an X-R-G structure, wherein X is a photosensitizer unit, R is a linker, G is a polypeptide unit targeting PD-L1 protein, the photosensitizer is a porphyrin photosensitizer, and the excitation light wavelength of the photosensitizer is longer than 550 nm; the molar absorption coefficient at the maximum absorption wavelength longer than the wavelength of 550 nm is greater than 1000 M -1cm-1; the quantum yield of a triplet state exceeds 0.01; the linker is selected from the following structural formulas, wherein the amino side of the linker is connected to the photosensitizer unit, the carboxyl side of the linker is connected to the polypeptide unit, and n is an integer of 0-50; the binding constant of the polypeptide and h-PD-L1 is less than 20 µm. Combination therapy of immune checkpoint blockade and cytotoxicity induced by the photosensitive chimera based on photodegradation of PD-L1 protein in PD-1 / PD-L1 can cause stronger immune response than monotherapy, and thus the photosensitive chimera has great potential in enhancing antitumor therapy.

The present invention provides an antibody or fragment thereof having binding specificity for human solute carrier 34A2 (SLC34A2) protein. These antibodies are capable of binding to SLC34A2 with high affinity, and can mediate antibody dependent cytotoxicity (ADCC) and effectively induce endocytosis. Methods and uses for treating cancer are also provided.

Provided is a bispecific antibody against EGFR and c-MET. By means of engineering the amino acid sequences of the Fc segments of binding arms, a KIH structure is formed between the EGFR binding arm and C-Met binding arm of the bispecific antibody, thereby assembling a heterodimer. The bispecific antibody is capable of inhibiting the growth and proliferation of EGFR and / or c-Met positive human tumor cells, mediating antibody-dependent cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and mediating the internalization and degradation of dual target proteins of EGFR and c-MET, and also has a synergistic effect. The bispecific antibody is simple to prepare and stable in structure, and is expected to better meet clinical treatment requirements on the basis of a better tumor cell selectivity.

The invention provides an ervatamia divaricata extract as well as a preparation method and application of the ervatamia divaricata extract in resisting brain metastatic tumor. Pharmacological activity shows that the extract of ervatamia divaricata disclosed by the invention has remarkable cytotoxicity inhibition activity, and the inhibition effect of the extract is time-dependent and dose-dependent. The extract can inhibit the growth of breast cancer 4T1 brain metastases, and has no obvious adverse reaction on mice.

The invention belongs to the technical field of specific fluorescent probe detection, and particularly relates to a near-infrared fluorescent probe for detecting hydrazine hydrate as well as a preparation method and application of the near-infrared fluorescent probe. The structural formula of the near-infrared fluorescent probe is # imgabs0. The invention provides a preparation method for synthesizing the probe by taking xanthene dye and acetyl chloride as raw materials. By researching the fluorescence spectrum of the fluorescent probe, the selectivity of the probe on N2H4 is evaluated, the fluorescence intensity of the probe is determined to be obviously enhanced only in the presence of N2H4, and the fluorescence intensity is positively correlated with the concentration of N2H4; meanwhile, the probe has the characteristics of quick response and near-infrared emission; the fluorescent probe disclosed by the invention has relatively small cytotoxicity and can be applied to detection of HepG2 cell exogenous hydrazine hydrate.

The invention discloses high-purity recombinant collagen as well as a preparation method and application thereof, the recombinant collagen is composed of a recombinant collagen monomer, and the recombinant collagen monomer has an amino acid sequence as shown in any one of SEQ ID NO: 1-22. According to the present invention, the easy-to-break site and the hydrophobicity of the collagen are optimized, such that the obtained recombinant collagen monomer and the prepared recombinant collagen have characteristics of high cell activity (adhesion, migration and proliferation), high triple helix structure stability, high purity, no cytotoxicity, large-scale production, and production cost reduction.

The invention belongs to the field of biological medicine, and particularly relates to an antibacterial peptide for inhibiting staphylococcus aureus and pseudomonas aeruginosa and application of the antibacterial peptide. The antibacterial peptide CAMP648NC is a novel cationic antibacterial peptide, the minimum inhibitory concentrations of the antibacterial peptide CAMP648NC to pathogenic bacteria staphylococcus aureus and pseudomonas aeruginosa are 16 [mu] g / mL and 32 [mu] g / mL respectively, the antibacterial peptide CAMP648NC has extremely low cytotoxicity, and after human skin keratinocytes HaCat and bronchial epithelial cells BEAS-2B are treated by the antibacterial peptide CAMP648NC with the concentration of 128 [mu] g / mL for 24 hours, the survival rates of 110.4% and 87.3% are still kept. Due to the characteristics, the compound shows extremely high medical drug antibacterial value, and alternative medicinal resources are provided for clinically resisting the two human pathogenic bacteria in the future.

Described herein are polypeptides and related antibodies comprising a variant Fc domain. The variant Fc domain provide for stabilized Fc: Fc interactions when the poly-peptide(s), antibody or antibodies are bound to its target, antigen or antigens on the surface of a cell, thus providing for improved complement-dependent cytotoxicity (CDC).

The invention belongs to the technical field of biology, and particularly relates to antibacterial peptide based on large yellow croaker CXCL8 protein and application of the antibacterial peptide. The preparation method comprises the following steps: by taking a large yellow croaker CXCL8 protein as a template, intercepting a linear polypeptide of 13 amino acids, and carrying out carboxyl terminal amidation modification, so as to obtain the antibacterial peptide AVV13N, and the amino acid sequence of the antibacterial peptide AVV13N is Ala-Arg-Trp-Val-Arg-Arg-Val-Leu-Lys-Lys-Met-Val-NH2; the antibacterial peptide AVK13N is obtained by interchanging lysine at the 11th site and valine at the 13th site in an amino acid sequence of the antibacterial peptide AVV13N, and the amino acid sequence of the antibacterial peptide AVK13N is Ala-Arg-Trp-Val-Arg-Arg-Val-Leu-Lys-Lys-Val-Met-Lys-NH2. The molecular weights of the antibacterial peptides AVV13N and AVK13N are both 1669.12 Da, the isoelectric points of the antibacterial peptides AVV13N and AVK13N are both 12.44, and the antibacterial peptides AVV13N and AVK13N are both alkaline polypeptides. The antibacterial peptides AVV13N and AVK13N have broad-spectrum bactericidal activity and can be used for specifically killing gram-positive bacteria and gram-negative bacteria. In addition, the antibacterial peptides AVV13N and AVK13N have relatively weak hemolytic activity, relatively low cytotoxicity and good temperature stability, pH value stability and salt ion stability. The antibacterial peptides AVV13N and AVK13N provided by the invention can replace antibiotics and are applied to prevention and treatment of bacterial diseases.

The invention belongs to the technical field of polypeptides and biological medicines, and particularly relates to a WK7 series antibacterial peptide and application thereof in the aspects of resisting bacteria and preventing and treating diabetic foot, pneumonia and septicemia. According to the invention, a linear peptide WK7-line with an amino acid sequence of WKRWKRW is used as a minimum active unit, and modification is carried out to form a plurality of linear modified peptides; meanwhile, a cyclic peptide WK7-cyl is formed on the basis of the linear peptide WK7-line through cyclization, and the cyclic peptide WK7-cyl is further modified to form an annular modified peptide. The linear peptide WK7-line, the linear modified peptide, the cyclic peptide WK7-cyl and the cyclic modified peptide jointly form the WK7-series antibacterial peptide, and the WK7-series antibacterial peptide is artificially synthesized polypeptide, is small in molecular weight, easy to synthesize, free of cytotoxicity, almost free of hemolysis risk, high in sterilization speed and broad-spectrum antibacterial property and can be used for preparing the antibacterial peptide. The traditional Chinese medicine composition has a certain effect on prevention and treatment of diabetic foot ulcer, pneumonia and septicemia.

The invention discloses a mussel byssus polypeptide with antibacterial performance and application thereof.The mussel byssus polypeptide has an obvious inhibiting effect on gram-positive bacteria and gram-negative bacteria, can inhibit formation of biological membranes of the gram-positive bacteria and the gram-negative bacteria, shows different antibacterial activities on multiple drug-resistant bacteria, and has the advantages that the mussel byssus polypeptide can be used for preparing a drug-resistant agent; and the hydrogel has low cytotoxicity and good biocompatibility, and shows good adhesion capability. The polypeptide is short in peptide chain and small in molecular weight, is a micromolecular polypeptide with great value, shows wide application potential in multiple fields, and has important value in the fields of medicine preparation, medical equipment and daily chemical products.